Background: Diagnosis of the antiphospholipid syndrome (APS) is difficult as a result of
limited specificity of existing assays for detecting clinically relevant antiphospholipid …

INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of
circulating antiphospholipid antibodies in patients with thrombosis or pregnancy morbidity …

Objective To determine the prevalence of anti-beta2-glycoprotein I antibodies (anti-beta2-
GPI) in patients with systemic lupus erythematosus (SLE), and to assess their association …

The lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) are clinically relevant
because of their association with thrombosis and pregnancy loss. The group of …

The association of antiphospholipid antibodies with thrombosis and obstetric events defines
the antiphospholipid syndrome. A recent systematic review of the literature showed lupus …

In 1990, b2-glycoprotein I (b2-GPI) was shown to be the main protein cofactor involved in the
binding of antiphospholipid antibodies to anionic phospholipids [1–3]. The presence of b2 …

The predictive value (PV) and association of 4 antiphospholipid antibodies with clinical
manifestations of the antiphospholipid syndrome (APS) were evaluated in 90 patients with …

The antiphospholipid syndrome (APS) is defined by the persistent presence of
antiphospholipid antibodies in patients with a history of thrombosis and/or pregnancy …

Patients diagnosed with the antiphospholipid syndrome typically suffer from vascular
thrombosis, pregnancy morbidity, or a combination of the two. Due to the high prevalence of …

Antibodies against β2 glycoprotein I (anti-β2GPI) have been identified as the main
pathogenic autoantibody subset in anti-phospholipid syndrome (APS); the most relevant …